Sandbox Reserved 1550 - Revision history

Hana Alhuneidi at 05:49, 6 May 2019

Hana Alhuneidi — Mon, 06 May 2019 05:49:24 GMT

←Older revision		Revision as of 05:49, 6 May 2019
Line 34:		Line 34:

	- The urinary level of liver-type fatty acid binding protein (L-FABP)is associated with chronic kidney disease (CKD) and acute kidney injury.		- The urinary level of liver-type fatty acid binding protein (L-FABP)is associated with chronic kidney disease (CKD) and acute kidney injury.
		+
		+	- There is a correlation between fatty acid-binding proteins and atherosclerosis. Increased levels of serum fatty acid-binding protein 4 (FABP4) promote type 2 diabetes (T2DM) and acute ischemic stroke. Fatty acid-binding proteins (FABPs) are cytosolic fatty acid chaperones. Adipocyte fatty acid-binding protein are part of the lipid chaperone fatty acid-binding protein family, is produced in adipocytes and macrophages; gene expression is higher in adipocytes. Circulating AFABP levels are associated with the metabolic syndrome and obesity, type 2 diabetes, insulin resistance, atherogenic dyslipidemia, and fatty liver disease.
		+	Increased levels of FABP4 promotes endoplasmic reticulum stress in macrophages and upregulates pro-inflammatory cytokine production.

	== '''Relevance''' ==		== '''Relevance''' ==
		+
		+	FABPs control metabolic signaling pathways and participate in multiple enzymatic activities.
		+
		+	- Structure: 14-15 kDa protein molecules, bind strongly and reversibly to hydrophobic ligands.
		+
		+	- Have conformational switches which create folding and promote function thereby deciding the functional conformation.
		+
		+	- Expressed IFABP prevents mitochondria from being morphologically impaired and apoptosis created by Fatty acid ligands.

	== '''Structural highlights''' ==		== '''Structural highlights''' ==
Line 57:		Line 68:

	Watanabe S, Ichikawa D, Sugaya T, et al. Urinary Level of Liver-Type Fatty Acid Binding Protein Reflects the Degree of Tubulointerstitial Damage in Polycystic Kidney Disease. Kidney & Blood Pressure Research. 2018;43(6):1716-1729. doi:10.1159/000495389.		Watanabe S, Ichikawa D, Sugaya T, et al. Urinary Level of Liver-Type Fatty Acid Binding Protein Reflects the Degree of Tubulointerstitial Damage in Polycystic Kidney Disease. Kidney & Blood Pressure Research. 2018;43(6):1716-1729. doi:10.1159/000495389.
		+
		+	Li S, Bi P, Zhao W, et al. Prognostic Utility of Fatty Acid-Binding Protein 4 in Patients with Type 2 Diabetes and Acute Ischemic Stroke. Neurotoxicity Research. 2018;(2):309. doi:10.1007/s12640-017-9792-z.
		+
		+	Sarkar-Banerjee S, Chowdhury S, Sanyal D, Mitra T, Roy SS, Chattopadhyay K. The Role of Intestinal Fatty Acid Binding Proteins in Protecting Cells from Fatty Acid Induced Impairment of Mitochondrial Dynamics and Apoptosis. Cellular Physiology And Biochemistry: International Journal Of Experimental Cellular Physiology, Biochemistry, And Pharmacology. 2018;51(4):1658-1678. doi:10.1159/000495672.

Hana Alhuneidi at 05:24, 6 May 2019

Hana Alhuneidi — Mon, 06 May 2019 05:24:46 GMT

←Older revision		Revision as of 05:24, 6 May 2019
Line 24:		Line 24:

	== '''Disease''' ==		== '''Disease''' ==
		+
		+	- Abundant amount of FABP4 is linked to cardiovascular disease.
		+
		+	- FABP is elevated in patients with celiac disease.
		+
		+	- FABP7 is known to be correlated with cell renal carcinoma. The fatty acid binding protein is upregulated in brain tissue. Overexpression of FABP7 in RCC cells increases cell growth and promotes extracellular signal regulated kinases and activator of transcription 3 signaling.
		+
		+	- Epidermal Fatty Acid binding protein is associated with Sjögren syndrome, a chronic inﬂammatory autoimmune disease of the salivary glands.
		+
		+	- The urinary level of liver-type fatty acid binding protein (L-FABP)is associated with chronic kidney disease (CKD) and acute kidney injury.

	== '''Relevance''' ==		== '''Relevance''' ==
Line 37:		Line 47:

	Storch, Judith, and Lindsay McDermott. “Structural and functional analysis of fatty acid-binding proteins.” Journal of lipid research vol. 50 Suppl,Suppl (2009): S126-31. doi:10.1194/jlr.R800084-JLR200		Storch, Judith, and Lindsay McDermott. “Structural and functional analysis of fatty acid-binding proteins.” Journal of lipid research vol. 50 Suppl,Suppl (2009): S126-31. doi:10.1194/jlr.R800084-JLR200
		+
		+	Elie AGIM, Bloksgaard M, Sun WY, et al. Local enrichment of fatty acid-binding protein 4 in the pericardial cavity of cardiovascular disease patients. Plos One. 2018;13(11):e0206802. doi:10.1371/journal.pone.0206802.
		+
		+	Oldenburger IB, Wolters VM, Kardol-Hoefnagel T, Houwen RHJ, Otten HG. Serum intestinal fatty acid-binding protein in the noninvasive diagnosis of celiac disease. APMIS: Acta Pathologica, Microbiologica, Et Immunologica Scandinavica. 2018;126(3):186-190. doi:10.1111/apm.12800.
		+
		+	Nagao K, Shinohara N, Smit F, et al. Fatty acid binding protein 7 may be a marker and therapeutic targets in clear cell renal cell carcinoma. BMC Cancer. 2018;18(1):1114. doi:10.1186/s12885-018-5060-8.
		+
		+	Shinzawa M, Dogru M, Den S, et al. Epidermal Fatty Acid-Binding Protein: A Novel Marker in the Diagnosis of Dry Eye Disease in Sjögren Syndrome. International Journal Of Molecular Sciences. 2018;19(11). doi:10.3390/ijms19113463.
		+
		+	Watanabe S, Ichikawa D, Sugaya T, et al. Urinary Level of Liver-Type Fatty Acid Binding Protein Reflects the Degree of Tubulointerstitial Damage in Polycystic Kidney Disease. Kidney & Blood Pressure Research. 2018;43(6):1716-1729. doi:10.1159/000495389.

Darshanie Munna at 20:53, 27 April 2019

Darshanie Munna — Sat, 27 Apr 2019 20:53:12 GMT

←Older revision		Revision as of 20:53, 27 April 2019
Line 1:		Line 1:
	<Structure load='1tou' size='350' frame='true' align='right' caption='Fatty Acid Binding Protein' scene='Insert optional scene name here' />{{ Sandbox_Reserved_GGC_BHCM4100_1}}<!-- PLEASE ADD YOUR CONTENT BELOW HERE -->		<Structure load='1tou' size='350' frame='true' align='right' caption='Fatty Acid Binding Protein' scene='Insert optional scene name here' />{{ Sandbox_Reserved_GGC_BHCM4100_1}}<!-- PLEASE ADD YOUR CONTENT BELOW HERE -->
	== '''Fatty Acid Binding Protein''' ==		== '''Fatty Acid Binding Protein''' ==
		+	Intracellular lipid chaperones known as fatty acid-binding proteins (FABPs) are a group of molecules that coordinate lipid responses in cells and are also strongly linked to metabolic and inflammatory pathways. FABPs are abundantly expressed 14–15 kDa proteins that reversibly bind hydrophobic ligands, such as saturated and unsaturated long-chain fatty acids, eicosanoids and other lipids, with high affinity.

	This is a default text for your page ''''''. Click above on '''edit this page''' to modify. Be careful with the < and > signs.		This is a default text for your page ''''''. Click above on '''edit this page''' to modify. Be careful with the < and > signs.
Line 6:		Line 7:

	== '''Function''' ==		== '''Function''' ==
		+	Fatty Acids Binding Proteins maintain intracellular lipid homeostasis and also affect systemic lipid metabolism. They have very unique features that allow them to transport and metabolize long chain fatty acids. Studies have suggested that subtle three dimensional changes that occur upon ligand binding may promote specific FABP-protein or FABP-membrane interactions that ultimately determine the particular function of the FABP.
		+
		+	FABPs play a role in the transport of lipids to specific compartments in the cell:
		+
		+	- to lipid droplets for storage;
		+
		+	- to the endoplasmic reticulum for signalling, trafficking and membrane synthesis;
		+
		+	- to the mitochondria or peroxisome for oxidation;
		+
		+	- to cytosolic or other enzymes to regulate their activity;
		+
		+	- to the nucleus for the control of lipid-mediated transcriptional programs via nuclear hormone receptors (NHRs) or other transcription factors that respond to lipids;
		+
		+	- or even outside the cell to signal in an autocrine or paracrine manner.

	== '''Disease''' ==		== '''Disease''' ==
Line 19:		Line 35:
	== '''Reference''' ==		== '''Reference''' ==
	Ringom, Rune; Axen, Eva; Uppenberg, Jonas; Lundbäck, Thomas; Rondahl, Lena; Barf, Tjeerd. (2004), Substituted benzylamino-6-(trifluoromethyl)pyrimidin-4(1H)-ones: a novel class of selective human A-FABP inhibitors. Elsevier BV., 14:4449-4452. https://doi.org/10.1016/j.bmcl.2004.06.058		Ringom, Rune; Axen, Eva; Uppenberg, Jonas; Lundbäck, Thomas; Rondahl, Lena; Barf, Tjeerd. (2004), Substituted benzylamino-6-(trifluoromethyl)pyrimidin-4(1H)-ones: a novel class of selective human A-FABP inhibitors. Elsevier BV., 14:4449-4452. https://doi.org/10.1016/j.bmcl.2004.06.058
		+
		+	Storch, Judith, and Lindsay McDermott. “Structural and functional analysis of fatty acid-binding proteins.” Journal of lipid research vol. 50 Suppl,Suppl (2009): S126-31. doi:10.1194/jlr.R800084-JLR200

Darshanie Munna at 20:21, 27 April 2019

Darshanie Munna — Sat, 27 Apr 2019 20:21:13 GMT

←Older revision		Revision as of 20:21, 27 April 2019
Line 12:		Line 12:

	== '''Structural highlights''' ==		== '''Structural highlights''' ==
		+	<Structure load='1tou' size='350' frame='true' align='center' caption='Fatty Acid Binding Protein' scene='Insert optional scene name here' />

	This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.		This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.

Darshanie Munna at 20:09, 27 April 2019

Darshanie Munna — Sat, 27 Apr 2019 20:09:35 GMT

←Older revision		Revision as of 20:09, 27 April 2019
Line 1:		Line 1:
	<Structure load='1tou' size='350' frame='true' align='right' caption='Fatty Acid Binding Protein' scene='Insert optional scene name here' />{{ Sandbox_Reserved_GGC_BHCM4100_1}}<!-- PLEASE ADD YOUR CONTENT BELOW HERE -->		<Structure load='1tou' size='350' frame='true' align='right' caption='Fatty Acid Binding Protein' scene='Insert optional scene name here' />{{ Sandbox_Reserved_GGC_BHCM4100_1}}<!-- PLEASE ADD YOUR CONTENT BELOW HERE -->
	== '''Fatty Acid Binding Protein''' ==		== '''Fatty Acid Binding Protein''' ==
-	~~<StructureSection load='1tou' size='340' side='right' caption='Fatty Acid Binding Protein' scene=''>~~	+
	This is a default text for your page ''''''. Click above on '''edit this page''' to modify. Be careful with the < and > signs.		This is a default text for your page ''''''. Click above on '''edit this page''' to modify. Be careful with the < and > signs.

Darshanie Munna at 01:04, 12 February 2019

Darshanie Munna — Tue, 12 Feb 2019 01:04:02 GMT

←Older revision		Revision as of 01:04, 12 February 2019
Line 3:		Line 3:
	<StructureSection load='1tou' size='340' side='right' caption='Fatty Acid Binding Protein' scene=''>		<StructureSection load='1tou' size='340' side='right' caption='Fatty Acid Binding Protein' scene=''>
	This is a default text for your page ''''''. Click above on '''edit this page''' to modify. Be careful with the < and > signs.		This is a default text for your page ''''''. Click above on '''edit this page''' to modify. Be careful with the < and > signs.
-	~~You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10.1002/ijch.201300024</ref> or to the article describing Jmol <ref>PMID:21638687</ref> to the rescue.~~	+

	== '''Function''' ==		== '''Function''' ==

Darshanie Munna at 01:00, 12 February 2019

Darshanie Munna — Tue, 12 Feb 2019 01:00:27 GMT

←Older revision		Revision as of 01:00, 12 February 2019
Line 16:		Line 16:

	</StructureSection>		</StructureSection>
-	== ~~References~~ ==	+	== '''Reference''' ==
-	~~<references~~/>	+	Ringom, Rune; Axen, Eva; Uppenberg, Jonas; Lundbäck, Thomas; Rondahl, Lena; Barf, Tjeerd. (2004), Substituted benzylamino-6-(trifluoromethyl)pyrimidin-4(1H)-ones: a novel class of selective human A-FABP inhibitors. Elsevier BV., 14:4449-4452. https://doi.org/10.1016/j.bmcl.2004.06.058

Darshanie Munna at 00:48, 12 February 2019

Darshanie Munna — Tue, 12 Feb 2019 00:48:38 GMT

←Older revision		Revision as of 00:48, 12 February 2019
Line 1:		Line 1:
	<Structure load='1tou' size='350' frame='true' align='right' caption='Fatty Acid Binding Protein' scene='Insert optional scene name here' />{{ Sandbox_Reserved_GGC_BHCM4100_1}}<!-- PLEASE ADD YOUR CONTENT BELOW HERE -->		<Structure load='1tou' size='350' frame='true' align='right' caption='Fatty Acid Binding Protein' scene='Insert optional scene name here' />{{ Sandbox_Reserved_GGC_BHCM4100_1}}<!-- PLEASE ADD YOUR CONTENT BELOW HERE -->
-	==Fatty Acid Binding Protein==	+	== '''Fatty Acid Binding Protein''' ==
	<StructureSection load='1tou' size='340' side='right' caption='Fatty Acid Binding Protein' scene=''>		<StructureSection load='1tou' size='340' side='right' caption='Fatty Acid Binding Protein' scene=''>
	This is a default text for your page ''''''. Click above on '''edit this page''' to modify. Be careful with the < and > signs.		This is a default text for your page ''''''. Click above on '''edit this page''' to modify. Be careful with the < and > signs.
	You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10.1002/ijch.201300024</ref> or to the article describing Jmol <ref>PMID:21638687</ref> to the rescue.		You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10.1002/ijch.201300024</ref> or to the article describing Jmol <ref>PMID:21638687</ref> to the rescue.

-	==	+	== '''Function''' ==
-	== Function	+
-	~~== Function ==~~	+
-	==	+

-	== Disease ==	+	== '''Disease''' ==

-	== Relevance ==	+	== '''Relevance''' ==

-	== Structural highlights ==	+	== '''Structural highlights''' ==

	This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.		This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.

Darshanie Munna at 00:46, 12 February 2019

Darshanie Munna — Tue, 12 Feb 2019 00:46:40 GMT

←Older revision		Revision as of 00:46, 12 February 2019
Line 6:		Line 6:

	==		==
		+	== Function
	== Function ==		== Function ==
	==		==

Darshanie Munna at 00:45, 12 February 2019

Darshanie Munna — Tue, 12 Feb 2019 00:45:57 GMT

←Older revision		Revision as of 00:45, 12 February 2019
Line 5:		Line 5:
	You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10.1002/ijch.201300024</ref> or to the article describing Jmol <ref>PMID:21638687</ref> to the rescue.		You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10.1002/ijch.201300024</ref> or to the article describing Jmol <ref>PMID:21638687</ref> to the rescue.

		+	==
	== Function ==		== Function ==
		+	==

	== Disease ==		== Disease ==